The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME Credit.
Read More
We publish an issue on antipsychotics at least once a year, and it’s always a challenge to decide what to cover. There are dozens of antipsychotics, and most of them are approved for mood disorders as well as psychosis.
Read More
For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe.
Read More
You’ve probably heard about a new “digital pill” called Abilify MyCite. The product, which was FDA approved in November 2017, is the first drug in the U.S. with a digital ingestion tracking system.
Read More
For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe.
Read More
Many of the medications we prescribe, most notably antipsychotics and antidepressants, have some risk of QTc prolongation. Since it’s rare to have complications of a prolonged QTc interval—such as torsades de pointes (TdP) and sudden cardiac death—clinics and hospitals typically don’t screen for it using electrocardiograms (ECG).
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
